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A B S T R A C T
Human papillomavirus (HPV) is known to play an important etiological role in the genesis of cervical cancer, but only
a very small proportion of infected women develop invasive cervical cancer. The purpose of cervical cancer prevention is
early diagnosis of its precursors. The molecular detection of HPV DNA as a diagnostic test to cervical carcinogenesis
gave a low positive predictive value as compared to the use of biomarkers. p16INK4a has been proposed as putative surro-
gate biomarkers that would allow identification of dysplastic cervical epithelia. Serial consecutive cervical smears were
test for high-risk HPV, stained with immunocytochemistry for p16INK4a and followed-up for 36 months. The aim of the
study was to evaluate the immunohistochemical expression of p16INK4a as a marker of progression risk in low-grade
dysplastic lesions of the cervix uteri. In the present series, significant p16 overexpression was observed in the group that prog-
ressed from low to high-grade squamous intraepithelial lesion when compared with the group that did not progress. In con-
clusion, overexpression of p16INK4a acts as potential biomarkers for cervical cancer progression from premalignant lesions.
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Introduction
Epidemiological and molecular studies over the past
two decades have demonstrated that high-risk human
papillomavirus (HR-HPV) types are etiologically related
to the progression to cervical cancer. Although more that
85 types of HPV have been detected in the genital mu-
cosa, in the majority of HPV-infected individuals, the vi-
rus is eliminated. A substantial proportion of HPV lesion
regresses spontaneously over 6–18 months period. Sev-
eral studies have shown that viral persistence is neces-
sary for cervical intraepithelial neoplasia (CIN) lesions to
progress or in fact be maintained.
Although HPV testing has been successfully used and
proposed for triaging to colposcopy those patients with
minor cytologic abnormalities, its positive predictive va-
lue (PPV) is suboptimal and a substantial proportion of
patients are still referred unnecessarily to colposcopy. In
the ALTS study1 the PPV for CIN3 of a positive HR-HPV
test in a patient with and atypical squamous cells of un-
determined significance (ASCUS) Pap was only 10%.
Identifying other molecular events associated with
progression from low (L)- to high (H)-grade squamous
intraepilelial lesions (SIL) is a crucial area of research, as
it may further improve selection of HPV-positive pa-
tients really worthy of assessment and treatment.
The use of modulators involved in the cell cycle as
biomarkers of HR-HPV infected cells may be an impor-
tant tool in the future to identifying those smears con-
taining HSIL of patients that might progress and develop
to cervical carcinoma.
The p16INK4 is a tumour suppressor protein that in-
hibits the function of cdk4 and cdk6, which in turn regu-
late the G1 checkpoint. CDK/cyclin-D phosphorylate the
retinoblastoma protein (pRb), resulting in a conforma-
tional change, with the release of E2F from Rb. Thus, in-
activation of either p16 or Rb function allows the cell to
enter the S phase after only a brief pause as the G1
checkpoint. In addition, the E6 HPV oncoprotein has the
ability to bind p53, resulting in its degradation, and the
E7 gene product inactivates the pRb pathway.
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Pathogenic activity of HR-HPV indicated by p16 ex-
pressions on smears could be a strategy to identify pa-
tients at major risk to develop cervical lesions.
The p16INK4a immunostaining has been suggested as a
tool for triaging women with low-grade or borderline cy-
tology; p16 could be particularly interesting among wo-
men with LSIL cytology, where triage by HPV is ineffi-
cient. Several studies2,3 reported a differential expression
of p16 in HSIL, LSIL and normal cervical epithelial cells.
The p16INK4a has been shown to be associated with
HPV-infected high grade lesions but its PPV and sensi-
tivity in prospective follow-up for relevant outcomes (>
CIN2) has yet to be determined.
In our previous report4 we assessed the accuracy of
p16 and HR-HPV testing in identifying high-grade cervi-
cal lesions in 283 cervical samples (ThinPrep) on a con-
secutive series of women referred to colposcopy for ab-
normal cytology (ASCUS). In this follow-up study we
analyzed the role of immunocytochemical expression of
p16 in HPV infected women as prognostic markers of the
progression of SIL.
Subjects, Material and Methods
Initially we assessed p16INK4a immunostaining and
HR-HPV in 283 patients consecutively referred to colpo-
scopy for cytologic evidence of LSIL or ASCUS within the
Florence (Italy) District screening programme for cervi-
cal cancer.
HPV and p16 testing were performed in the whole se-
ries prior to colposcopy assessment: cervical material
was collected using ThinPrep® (Cytic Corp., Boxborough,
MA), allowing for multiple slide preparation and residual
fluid. Laboratory operators performing the testing were
blinded to the colposcopy assessment outcome. The pa-
tients without CIN2 or more were invited regularly for
follow-up cytology; if cytology was ASCUS or more col-
poscopy was performed.
The 238 out of 252 patients were followed for 36
month period and then stratified according the cytology
results and final outcome. Final outcome was defined ac-
cording to colposcopy-directed biopsy result (<CIN2 or
>CIN2) and was assumed to be negative in the presence
of negative colposcopy, indicating no biopsy. Observed
differences were tested by the Chi-square test, with sta-
tistical significance set at p <0.05.
HPV and p16 testing were performed in the whole se-
ries prior to colposcopy assessment: cervical material
was collected using ThinPrep® (Cytic Corp., Boxborough,
MA), allowing for multiple slide preparation and residual
fluid. Laboratory operators performing the testing were
blinded to the colposcopy assessment outcome.
HPV Testing
From each specimen, 2 mL of residual ThinPrep fluid
was used, and DNA extraction was carried out using a
QIAmp DNA Mini Kit (Qiagen Corporation, Venlo, the
Netherlands) according to the manufacturer’s protocol.
Polymerase chain reaction (PCR) analysis was performed
according to a previously described protocol5 using prim-
ers for the E6/E7 region of HR HPV types (HPV 16, 18,
31, 33, 35, 45, 52 and 58). For a quality control of DNA
extraction, the primer set PC04 and Gh20 was employed
to amplify a 268-base pair (bp) fragment of the human
beta globin gene in all specimens. In each PCR reaction,
negative and positive controls were introduced.
p16INK4a Testing
From each specimen, 2 mL of residual ThinPrep fluid
was used for a cytospin preparation; after cytocentri-
fugation (5 min at 1000 rpm), slides were air dried for 10
minutes, then treated with spray fixation reagent, con-
taining polyethylene glycol, and immunostained within
24 hours. Before they were immunostained, all spray-
fixed specimens were incubated in 50% volume/volume
alcohol, followed by one washing step in deionized water.
For immunostaining, CINtectm p16 Cytology kit (Dako
Cytomation, now Dako A S, Glostrup, Denmark) was
used, according to the manufacter’s protocol. In brief,
smears were treated with 3% hydrogen peroxide and
then submitted for epitope retrieval at 95–99 °C for
40(±1) minutes; after cooling, the p16INK4a antibodies
were applied for 30 (±1) minutes and then a reagent for
observation and substrate-chromogen solutions were ad-
ded. Hematoxylin was used as counter stain. The method-
ology differs from other studies on p166,7, but we used the
samemonoclonal antibody and believe that the results are
comparable. The choice of cytospin preparation was es-
sentially aimed at a more efficient use of the residual
ThinPrep fluid. Before the study, we made a comparison
of p16INK4a testing on cytospin and ThinPrep preparations
on limited numbers of negative and positive samples (data
not shown), and we observed no differences.
Slides were read by two investigators blinded to final
outcome, and a minimum of 500 cells in different fields
were analyzed. A negative result was defined if no cells
immunoreactive to the p16INK4a antibody were in evi-
dence. Slides showing positive staining for p16 were cate-
gorized on the basis of the percentage of positive cells as:
<5%, 5–10% or >10%. The cellular staining site was also
evaluated and categorized as 1) nuclear, 2) cytoplasmic,
or 3) nuclear plus cytoplasmic.
Results
At recruitment4 we assessed the accuracy of p16 and
HR-HPV testing in identifying high-grade cervical lesions
in 283 cervical samples (ThinPrep) on a consecutive series
of women referred to colposcopy for abnormal cytology
(ASCUS). The results were compared with colposcopy
and biopsy findings. HPV positivity rate was 44.2% among
<CIN1, and 89.2% among CIN2 patients (Chi-square for
trend <10–6). The sensitivity, specificity, and PPV of HPV
testing for CIN2 were 89.2% (25 of 28), 47.8 (122of 255)
and 15.8% (28 of 158), respectively. P16 positivity rate was
25.3% among <CIN1, 57.4% among CIN1 and 88.0%
among >CIN2 patients (square for trend <10–6). Sensitiv-
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ity for CIN2 was 88% (22 of 25), specificity was 61.2% (79
of 129) and PPV was 30.5% (22 of 72).
The patients with cytological abnormalities but with-
out CIN2/3 lesions were followed-up, for 36 months by
cytology and colposcopy was performed if cytology was
ASCUS or worse.
Between 252 patients, 215 women have had a follow-
up procedure: 108/122 (88%) with a negative result for
HR-HPV and 107/130 with a positive result for HR-HPV.
After 36 months (Table1), 8 (7.4%) women with a neg-
ative result for HR-HPV at recruitment, still displayed
abnormal smears (3 ASCUS, 3 LSIL and 2 HSIL). Final
outcome of these cases was: 2 CIN2 (1.8%), 3 CIN1
(2.8%) and 3 Negative (2.8%).
Between women with a positive result for HR-HPV at
enrolment (Table1), after 36months of follow-up, 18 (16.8%)
women still displayed abnormal smears (2 ASCUS, 10 LSIL
and 6 HSIL). Final outcome of these cases was: 9 CIN2+
(8.4%), 3 CIN1 (2.8%) and 6 Negative (5.6%), (p <0.05).
Considering p16 immunostaing, 66/79 (84%) p16 neg-
ative and 40/50 (80%) p16 positive have had follow-up
(Table 2). During the follow-up of p16 negative women 3
(3/66=4.5%) CIN2 were founded, while 6 CIN2 (6/40=
15%) were founded in p16 positive women (p<0.05).
At the enrolment the number of p16 positive cells did
not correlate with the probability of CIN2 (<5% =
36.3%, 5–10% = 27.2%, >10% = 36.3) and was no fur-
ther considered a relevant variable. No evident differen-
ces in pattern or intensity of p16 expression were ob-
served between the specimens with high grade lesions
and without high lesions at follow-up.
Discussion
HPV DNA testing appears useful in the triage of
equivocal Pap-smears; however studies could not demon-
strate a high level of specificity of HPV DNA testing for
clinically significant cervical disease. The p16 immuno-
staining has been suggested as a tool for triaging women
with low-grade or borderline cytology; p16 could be par-
ticularly interesting among women with LSIL cytology,
where triage by HPV is inefficient. Moreover, an obvious
problem in using HPV testing as a screening tool is that a
sizable proportion of normal women are HPV positive;
however a report8 suggested that about 15% of women in
annual screening programme who concurrently have a
negative Pap test and a positive oncogenic HPV test will
have a subsequent abnormal Pap test within 5 years.
Nevertheless, HPV testing also identified many tran-
sient HPV infections that are not associated with high-
grade CIN. Several studies based on molecular markers
associated with HPV infection could facilate and optimise
diagnosis in a screening setting. It may be possible to de-
tect clinically important disease with risk of progression
towards dysplasia and carcinoma, and consequently, im-
prove patient care by combining test results from molecu-
lar markers with either cytology or HPV or both.
Several studies2–4 reported a differential expression of
p16 in HSIL, LSIL and normal cervical epithelial cells.
In this study, we evaluated the potential of p16 immu-
nocytochemical expression to predict the course of cytologi-
cal cervical abnormalities associated with HR-HPV types.
In the present series, significant p16 overexpression
was observed in the group that progressed from LSIL to
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TABLE 1
HPV TEST AT RECRUITMENT ACCORDING TO THE CYTOLOGICAL DIAGNOSIS DURING THE FOLLOW-UP
N (%) of HR-HPV negative N (%) of HR-HPV positive Total – N (%)
Normal 100 (92.6) 89 (83.2) 189 (87.9%)
ASCUS 3 (2.8) 2 (1.9) 5 (2.3%)
LSIL 3 (2.8) 10 (9.3) 13 (6.04%)
HSIL 2 (1.8) 6 (5.6) 8 (3.7%)
Total 108 (50.2%) 107 (49.8%) 215
HR – high-risk, HPV – human papillomavirus, ASCUS – atypical squamous cells of undetermined significance, LSIL – low-grade
squamous intraepilelial lesions, HSIL – high-grade squamous intraepilelial lesions
TABLE 2
P16 AT RECRUITMENT ACCORDING TO THE CYTOLOGICAL DIAGNOSIS DURING THE FOLLOW-UP
N (%) of p16INK4a negative N (%) of p16INK4a positive Total – N (%)
Normal 58 (87.9) 31 (77.5) 89 (84.0)
ASCUS 1 (1.5) 1 (2.5) 2 (1.9)
LSIL 6 (9.1) 4 (10) 10 (9.4)
HSIL 1 (1.5) 4 (10) 5 (4.7)
Total 66 (62.3) 40 (37.7) 106
HR – high-risk, HPV – human papillomavirus, ASCUS – atypical squamous cells of undetermined significance, LSIL – low-grade
squamous intraepilelial lesions, HSIL – high-grade squamous intraepilelial lesions
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HSIL when compared with the group that did not prog-
ress. To our knowledge, there are a few studies with a
prospective follow-up design carry out to evaluate SIL
progression and the association of p16 overexpression in
cervical specimens in a screening setting for cervical cancer.
Although p16 protein and HPV infection may be de-
tected in low-grade lesions or reactive changes that un-
dergo spontaneous regressions, Wang9 et al. found that
the risk for CIN progression or HPV persistent is higher
for women with diffuse staining for p16 protein com-
pared with those without diffuse staining in tissue sam-
ples. Negri10 also found that CIN1 cases with diffused
p16 staining had significant higher tendency to progress
to a high-grade lesion that p16 protein negative cases.
Conclusion
This study suggest that the combined use of p16 pro-
tein and HPV testing may be useful in identifying cervi-
cal cells with minor abnormalities and a high risk of pro-
gressing to cervical neoplasia, and also defining cases
requiring early management, or at least close surveil-
lance. Our study demonstrated that p16 evaluation on
ThinPrep samples could be useful as a biomarker for pro-
gressive malignancy in HPV-related cytological abnor-
malities. Patients with ASCUS or LSIL and HR-HPV and
p16 positive test were a major risk to develop high grade
lesion compared with patients HR-HPV negative or HR-
HPV positive but with p16 negative.
These findings suggest that among HPV positive pa-
tients, there is a subgroup that may be at increased risk of
progression to invasive cancer and should be followed-up
more closely. Theoretically, all HR HPV-associated lesions
should express p16INK4a. It is unclear why some CIN2 sam-
ples that are HPV DNA positive were also p16INK4a nega-
tive. Wemight assume that there are other mechanisms of
p16INK4a regulation besides HPV infection, such as pro-
moter methylation, that could occur in cervical cancer.
However, according to previous report in the literature,
pRb inactivation via the p16/cdk-cyclin/ RB pathway and
increase in p16 expression in HPV- transformed cells is an
important mechanism for cervical carcinogenesis.
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KOMBINIRANA ANALIZA DNA HPV-A I EKSPRESIJE P16 U PREDVI\ANJU
PROGNOZE PAPA-NALAZA ASCUS I LSIL
S A @ E T A K
Poznato je da humani papilomavirus (HPV) igra va`nu etiolo{ku ulogu u nastanku raka vrata maternice, no samo
mali udio inficiranih `ena zaista i razvije invazivni rak vrata maternice. Cilj prevencije raka vrata maternice je rana
dijagnoza njegovih prekursora. Molekularna detekcija DNK HPV-a kao dijagnosti~ki test za karcinogenezu raka vrata
maternice je dala slabo pozitivne prediktivne vrijednosti u usporedbi s upotrebom biolo{kih biljega. p16INK4a je pred-
lo`en kao osnovni biljeg koji bi omogu}io identifikaciju promjena epitela vrata maternice. Grupa uzastopnih obrisaka
vrata maternice je testirana na visokorizi~ne HPV, obojana imunocitokemijski za detekciju p16INK4a i pra}ena 36 mjese-
ci. Cilj studije je bio procijeniti imunohistokemijsku ekspresiju p16INK4a kao biljega rizika progresije u o{te}enjima nis-
kog stupnja stanica vrata maternice. U toj grupi je zabilje`ena znatno pove}ana ekspresija p16 za skupinu koja je pre{la
iz o{te}enja niskog stupnja u o{te}enja stanica vrata maternice visokog stupnja u usporedbi sa skupinom kod koje nije
do{lo do progresije. Zaklju~ili smo da pove}ana ekspresija p16INK4A djeluje kao mogu}i biolo{ki biljeg koji ukazuje na
progresiju o{te}enja vrata maternice u premaligni i maligni stadij.
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